8-K: Innovative MedTech Secures High-Cost Convertible Debt, Signaling Financial Strain

Innovative MedTech, Inc. has entered into two high-interest convertible promissory note agreements totaling $83,000 in net funding, indicating a reliance on expensive financing for general working capital.

Summary

• Innovative MedTech, Inc. (the 'Company') has secured $83,000 in net funding through two separate convertible promissory notes with 1800 Diagonal Lending LLC.
• The first note has a principal amount of $66,700, purchased for $58,000, with a one-time interest charge of 12% ($8,004) and an original issue discount (OID) of $8,700.
• The second note has a principal amount of $28,750, purchased for $25,000, with a one-time interest charge of 14% ($4,025) and an OID of $3,750.
• Total principal amount across both notes is $95,450, with a combined purchase price of $83,000.
• An $8,000 legal and due diligence fee was retained by the lender from the purchase price of the first note, resulting in a net funding of $75,000 to the Company.
• Both notes mature on March 30, 2026, and include mandatory monthly payments, totaling $74,704 for the first note and $32,775 for the second note, if paid in cash.
• In case of default, the notes bear a high default interest rate of 22% per annum, and the outstanding amount becomes immediately due at 150% of the principal plus accrued interest and default interest.
• Upon default, the holder has the option to convert the outstanding balance into common stock at a conversion price equal to the greater of $0.01 or 71% of the lowest trading price during the ten trading days prior to conversion, subject to a 4.99% beneficial ownership limitation.
• The Company is required to reserve four times the number of shares issuable upon full conversion of the notes (initially 3,352,137 shares for the first note and 1,444,886 shares for the second note) to facilitate potential conversions.
• Proceeds from these transactions are designated for general working capital purposes.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the extremely unfavorable terms of the convertible debt, including high interest rates, significant original issue discounts, and highly dilutive conversion features. These terms suggest the Company is in a precarious financial position and has resorted to very expensive and potentially damaging financing to sustain operations, posing substantial risks to existing shareholders.

Positives

• The Company successfully secured $75,000 in net funding, providing capital for general working capital purposes.
• The notes allow for prepayment in full at any time with no prepayment penalty, offering some flexibility to the Company if it can secure better financing or generate sufficient cash flow.

Negatives

• The financing terms are highly unfavorable, characterized by significant original issue discounts ($12,450 combined) and high one-time interest charges (12% and 14%), leading to a substantial difference between funds received and principal owed.
• The effective cost of capital is very high, reflecting the Company's likely distressed financial position and limited access to conventional financing.
• The conversion terms are highly dilutive, allowing conversion at 71% of the lowest trading price or a floor of $0.01, which could significantly devalue existing shareholder equity if the stock price declines or defaults occur.
• Punitive default provisions include a 22% default interest rate and a mandatory prepayment amount of 150% of the outstanding principal plus interest upon an Event of Default.
• A $1,500 fee can be deducted by the holder from each conversion amount, further increasing the cost to the Company.
• The Company is subject to a $2,000 per day 'Fail to Deliver Fee' if it fails to deliver common stock upon conversion by the deadline, which can be added to the principal amount of the note.

Risks

• High risk of significant shareholder dilution due to the highly unfavorable conversion price mechanism (71% of lowest trading price or $0.01 floor) upon an Event of Default.
• Risk of financial distress and potential bankruptcy given the high cost of debt and punitive default terms, including a 150% penalty on outstanding amounts.
• Operational constraints as the Company is prohibited from selling a significant portion of its assets outside the ordinary course of business without the lender's consent.
• Risk of delisting of common stock if the Company fails to maintain its listing on specified exchanges, which constitutes an Event of Default.
• Risk of non-compliance with Exchange Act reporting requirements, which would also trigger an Event of Default.
• Potential for cross-default with other existing and future debt if the Company breaches covenants in other agreements with the same lender or its affiliates.
• The requirement to maintain four times the number of shares for conversion could strain the Company's authorized share capital and potentially lead to further dilution or inability to raise capital through equity if the reserved amount is not maintained.

Future Outlook

The Company intends to use the proceeds from these convertible notes for general working capital purposes. The terms of the notes, particularly the high interest rates and dilutive conversion features, suggest a challenging financial outlook and a need for immediate liquidity, potentially indicating ongoing operational difficulties or limited access to more favorable financing options.

Management Comments

• Michael Jordan Friedman, Chief Executive Officer, signed the promissory notes and the Form 8-K report on behalf of Innovative MedTech, Inc.

Industry Context

This type of high-cost, dilutive convertible debt financing is often observed in small-cap companies, particularly those in the medical technology or biotechnology sectors, that may be pre-revenue, experiencing cash flow challenges, or have limited access to traditional bank loans or equity markets. The terms suggest that Innovative MedTech, Inc. is in a position where it must accept highly unfavorable financing to maintain operations, which is a common characteristic of companies facing significant financial constraints or perceived high risk by conventional lenders.

Comparison to Industry Standards

• The combined effective interest rate, considering the Original Issue Discount and one-time interest charges, is significantly higher than typical commercial loans or even venture debt for established companies, indicating a high-risk profile for Innovative MedTech, Inc. For instance, traditional bank loans for even high-growth companies rarely exceed prime plus a few percentage points, while these notes imply an annualized cost well into double digits.
• The conversion price mechanism, set at 71% of the lowest trading price during a 10-day period, is a 'death spiral' or 'toxic' financing feature. This is far more aggressive than standard convertible notes, which typically convert at a premium to the current market price or a fixed price. This structure almost guarantees significant dilution for existing shareholders as the lender can convert at increasingly lower prices, exacerbating downward pressure on the stock.
• The 22% default interest rate and 150% default prepayment penalty are extremely punitive compared to industry norms. Standard default rates are usually a few percentage points above the regular interest rate, and such high penalties are indicative of a lender taking aggressive measures to protect its investment in a high-risk scenario.
• The $8,000 legal and due diligence fee, while not exorbitant in absolute terms, represents a substantial percentage of the net funding received, further increasing the effective cost of capital for the Company, especially when compared to typical transaction costs for larger, more stable companies.

Corporate Governance

Legal Proceedings

• The document states that there is no action, suit, claim, proceeding, inquiry or investigation pending or threatened against the Company or its subsidiaries that could have a Material Adverse Effect, except as set forth in SEC Documents.

Stakeholder Impact

• **Shareholders**: Highly negative impact due to the significant potential for dilution from the convertible notes, especially given the 'toxic' conversion terms (71% of lowest trading price or $0.01 floor). The high cost of debt and punitive default provisions also increase financial risk, potentially leading to a decrease in share value.
• **Creditors**: The new debt introduces additional leverage and senior claims, potentially impacting the recovery prospects of other creditors in a distressed scenario. However, the lender (1800 Diagonal Lending LLC) has strong protective covenants and remedies, including high default interest and conversion rights, which prioritize their recovery.
• **Management/Employees**: The need for such expensive financing suggests ongoing financial challenges, which could lead to operational austerity, job insecurity, or difficulty in attracting and retaining talent if the company's financial health does not improve.

Next Steps

• The Company is obligated to make mandatory monthly payments on the notes, with the first payment for the First Note due June 30, 2025, and for the Second Note due November 30, 2025.
• The Company must ensure compliance with all covenants, including maintaining corporate existence, not selling significant assets without lender consent, and adhering to 1934 Act reporting requirements, to avoid triggering Events of Default.
• The Company needs to maintain sufficient authorized and unissued common stock (four times the conversion amount) to cover potential conversions by the holder.

Key Dates

Recommendation

Keywords

Convertible Promissory Note, Debt Financing, SEC Filing, Form 8-K, Innovative MedTech, 1800 Diagonal Lending LLC, Original Issue Discount, Dilution, Default Interest, Working Capital, Private Placement, Securities Purchase Agreement